ESHRE IVF实验室良好实践推荐
该文件为ESHRE按照预设方法学更新的IVF实验室良好实践推荐,工作组由10名来自欧洲不同国家与机构的成员组成,代表胚胎学、安全与质量及男科学特别兴趣组。推荐基于现有文献证据及工作组专家共识形成,经利益相关方审阅后由工作组及ESHRE执行委员会批准。更新内容涵盖实验室总体组织(人员与主任、质量管理、实验室安全)及具体操作(患者身份识别与配子追溯、耗材、生物材料处理、取卵、精子制备、授精、受精评分、胚胎培养与移植、胚胎活检、冷冻保存及紧急程序)。胚胎培养与移植章节被拆分,精子制备章节扩展至覆盖所有常规男科操作,并新增活检操作章节。原文指出并非所有推荐均有证据支持,部分推荐参考了法律文件、相关近期文件、手册及共识文件。
要点
- 该推荐覆盖IVF实验室全部操作:总体组织(人员与主任、质量管理、实验室安全)及具体操作(患者身份识别与配子追溯、耗材、生物材料处理、取卵、精子制备、授精、受精评分、胚胎培养与移植、活检、冷冻保存、紧急程序)。
- 工作组由10名成员组成,代表ESHRE胚胎学、安全与质量及男科学特别兴趣组,来自不同欧洲国家与机构。
- 胚胎培养与移植章节被拆分为独立章节,精子制备章节扩展至覆盖所有常规男科操作,并新增胚胎活检操作章节。
- 原文指出并非所有推荐均有证据支持,部分推荐在缺乏证据时参考了法律文件、相关近期文件、手册及共识文件。
- 推荐经利益相关方审阅初始草案后,最终版本由工作组及ESHRE执行委员会批准。
研究设计与关键结果
- 制定机构:ESHRE;工作组10名成员,代表胚胎学、安全与质量及男科学特别兴趣组,来自不同欧洲国家与机构。
- 方法:按ESHRE良好实践推荐预设方法学,工作组审阅2015版文件后各成员更新一个或多个章节,推荐基于现有文献数据(如有)及工作组专家共识,讨论至达成共识。
- 经利益相关方审阅初始草案后,最终版本由工作组及ESHRE执行委员会批准。
- 更新内容涵盖IVF实验室总体组织(人员与主任、质量管理、实验室安全)及具体操作(患者身份识别与配子追溯、耗材、生物材料处理、取卵、精子制备、授精、受精评分、胚胎培养与移植、胚胎活检、冷冻保存、紧急程序)。
- 胚胎培养与移植章节被拆分,精子制备章节扩展至覆盖所有常规男科操作,新增活检操作章节。
证据类型、等级与局限
- 证据类型:指南(ESHRE良好实践推荐)。
- 原文指出并非所有推荐均有证据支持;部分推荐参考了法律文件、相关近期文件、手册及共识文件。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文指出该文件对参与IVF实验室管理与组织的主任和管理者、以及执行日常任务的胚胎学家和实验室技术人员有帮助。
- 原文免责声明:遵守该临床实践指南不保证成功或特定结局,也不建立诊疗标准;临床实践指南不替代针对每个个体表现及根据地区和机构类型差异应用临床判断的需要。
指南或共识出处
- ESHRE Recommendations on Good Practice in the IVF laboratory(ESHRE,更新版;前一版2015年发布)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY QUESTION: What is the current good practice in the IVF laboratory, based on the best available evidence in the literature, if available, and the expertise of the working group?
SUMMARY ANSWER: The updated ESHRE Recommendations on Good Practice in the IVF laboratory provides recommendations on all activities in the IVF laboratory.
WHAT IS KNOWN ALREADY?: A previous version of the Good Practice in the IVF laboratory guideline was published in 2015. The adoption of new techniques, the increasing complexity of procedures, and the introduction of a revised European legislation on the quality and safety of tissues and cells for human application pertinent to assisted reproduction together necessitated an update of the document.
STUDY DESIGN, SIZE, DURATION: This document was developed according to a predefined methodology for ESHRE Good Practice recommendations. The working group reviewed the document of 2015, and based on this assessment, each group member updated one or more sections. Recommendations are supported by data from the literature, if available, and the expertise of the working group and were discussed until consensus was reached within the working group.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The working group included 10 members representing the ESHRE Special Interest Groups for Embryology, Safety and Quality, and Andrology, with different areas of expertise and representing different European countries and settings. Based on the available evidence and the expertise of the working group, recommendations were formulated. Following stakeholder review of the initial draft, the final version was approved by the working group and ultimately by the ESHRE Executive Committee.
MAIN RESULTS AND THE ROLE OF CHANCE: The ESHRE IVF labs working group updated the recommendations on the general organization of an IVF laboratory (staffing and direction, quality management, and laboratory safety) and on the specific aspects of the procedures performed in IVF laboratories (identification of patients and traceability of their reproductive cells, consumables, handling of biological material, oocyte retrieval, sperm preparation, insemination of oocytes, scoring for fertilization, embryo culture and transfer, embryo biopsy for pre-implantation genetic testing, cryopreservation, and emergency procedures). The section on embryo culture and transfer was split up, the section on sperm preparation was expanded to cover all general andrological procedures, and a new section on biopsy procedure was introduced.
LIMITATIONS, REASONS FOR CAUTION: Not all recommendations are supported by evidence. Other recommendations, published in legal documents, relevant and recent documents, manuals, and consensus papers, were taken into account when formulating the recommendations.
WIDER IMPLICATIONS OF THE FINDINGS: The guideline group is confident that this document will be helpful to directors and managers involved in the management and organization of IVF laboratories and also to embryologists and laboratory technicians performing daily tasks.
STUDY FUNDING/COMPETING INTEREST(S): The guideline was developed by ESHRE, which funded the guideline meetings, literature searches, and dissemination of the guideline. The guideline group members did not receive any financial incentives; all work was provided voluntarily. G.C. reports consulting fees from Gedeon Richter and Cooper Surgical and was part of the working group of the 'Guide to the quality and safety of tissues and cells for human application' of the European Directorate for the Quality of Medicines and Healthcare, on behalf of the Council of Europe. T.E. reports consulting fees from Nexpring Health and Esco Medical and speaker's fees from Nexpring Health and Esco Medical. J.K.-B. reports research grants from Gates Foundation and NIHR, consulting fees from Bayer, speakers fees from Merck, IBSA, Ferring and Cooper Surgical, and travel support from Merck, IBSA, Ferring, and Cooper Surgical. I.S. reports speaker's fees from Vitrolife and Cooper Surgical. I.S. also declares being a member of ARCS Scientific Committee. The other authors disclosed no conflicts of interest.
DISCLAIMER: This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. Adherence to these clinical practice guidelines does not guarantee a successful or specific outcome nor does it establish a standard of care. Clinical practice guidelines do not replace the need for application of clinical judgment to each individual presentation nor variations based on locality and facility type. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose (full disclaimer available at www.eshre.eu/guidelines).
参考来源
- Arroyo G, Barrie A, Coticchio G, et al. ESHRE recommendations on Good Practice in the IVF laboratory†. Hum Reprod. 2026. PMID: 42405499. doi:10.1093/humrep/deag096
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。